Addressing the Gap in Cancer Side Effect Management with Digital Solutions

Cisplatin, a widely used chemotherapy drug for head and neck squamous cell carcinoma (HNSCC), causes significant ototoxicity, leading to permanent hearing loss in patients. To prevent this, regular audiometry is recommended before and after chemotherapy and radiation therapy. However, due to patient discomfort and geographical limitations, participation in monitoring is often low. To address this, Emory University researchers have initiated a clinical trial (NCT06662058) to validate the effectiveness of remote audiometry, aiming to reduce barriers to monitoring and facilitate timely treatment adjustments. This goes beyond simple convenience, potentially shifting the focus from survival-centered treatment to a patient-centered, integrated healthcare model.

Maximizing Monitoring Accessibility and Clinical Protocol

This clinical study (Phase N/A, supportive care) involves a total of 118 head and neck cancer patients, divided into a standard in-person examination group and a remote examination group. Patients in the remote examination group, including those living more than 120 miles from the hospital or those with stage IV cancer, will receive self-administered remote audiometry or testing services near their residence. The study will compare completion rates at 3 and 12 months to demonstrate how effectively digital devices can replace traditional in-person visits. Improved healthcare access can enable early detection of hearing loss, leading to real-time treatment plan modifications, such as adjusting cisplatin dosage or radiation plans.

Synergy Between the Global Cancer Treatment and Digital Healthcare Markets

In 2025, the global market for head and neck cancer treatments is estimated at USD 2.5 billion, and it is projected to grow to USD 6.3 billion by 2033. Simultaneously, the digital health and telehealth markets are expected to grow from USD 77.4 billion in 2025 to over USD 180 billion in 2030, making the commercial value of cancer side effect monitoring solutions very high. Fennec Pharmaceuticals (FENC) received FDA approval for Pedmark (sodium thiosulfate) in September 2022 as a prophylactic drug for cisplatin-induced ototoxicity in pediatric patients, but there is currently no standard treatment for adults. Therefore, if this clinical trial demonstrates the usefulness of remote audiometry, it will provide new opportunities for collaboration between pharmaceutical companies and digital healthcare companies, creating a powerful catalyst for mutual growth.

Patient-Centered Values and Long-Term Changes in the Healthcare Ecosystem

Hearing loss is more than just sensory impairment; it can lead to social isolation, depression, and cognitive decline. For cancer patients, hearing loss can be a significant factor in reducing their will to live, so early monitoring and preservation of hearing play a crucial role in improving treatment adherence. The results of this study will provide an important precedent for expanding remote healthcare platforms to other areas of side effect monitoring, such as neurotoxicity and cardiotoxicity, in various cancer treatments. Ultimately, it will provide healthcare providers with cost-effective data for side effect management and create a patient-centered healthcare ecosystem that reduces suffering and accelerates recovery.